Review article: The role of non-biological drugs in refractory inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 4, 2011, Pages 417-427

  Ng, S C ^a   Chan, F K L ^a   Sung, J J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETARSOL; ALLOPURINOL; AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; FOLIC ACID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PROBIOTIC AGENT; STEROID; TACROLIMUS; THALIDOMIDE; TIOGUANINE; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; COLITIS; CROHN DISEASE; DIARRHEA; DOSE RESPONSE; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; ENTERIC FEEDING; ENTERITIS; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOMAGNESEMIA; KIDNEY DYSFUNCTION; LEUKAPHERESIS; LIVER HYPERPLASIA; LIVER TOXICITY; LOW DRUG DOSE; PARENTERAL NUTRITION; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROCTITIS; REMISSION; REVIEW; SYSTEMATIC REVIEW; TERATOGENICITY; TREMOR; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; DRUG RESISTANCE; ENTERAL NUTRITION; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS; PURINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 78751483914     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04541.x     Document Type: Review

References (111)

1. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
2. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76. (Pubitemid 41770166)
5. Thia KT, Loftus EV Jr, Sandborn WJ, et al. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol 2008; 103: 3167-82.
6. Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in incidence and prevalence of inflammatory bowel disease in a province of western Hungary between 1977-2001. World J Gastroenterol 2004; 10: 404-9.
7. Gearry RB, Irving PM,. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to? J Gastroenterol Hepatol 2009; 24: 1160-2.
8. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
9. Dignass A, Van AG, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's & Colitis 2010; 4: 28-62.
10. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-8.
11. Genestier L, Paillot R, Quemeneur L, et al. Mechanisms of action of methotrexate. Immunopharmacology 2000; 47: 247-57.
12. Rampton DS,. Methotrexate in Crohn's disease. Gut 2001; 48: 790-1.
13. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-21.
14. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
15. Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 385-9.
16. Nathan DM, Iser JH, Gibson PR,. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2007; 6: 954-8.
17. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009; 30: 614-20.
18. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-33.
19. Chande N, Macdonald JK, McDonald JW,. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; 4: CD006618.
20. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-9.
21. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 1627-32.
22. Lichtenstein GR, Sbreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Rev Gastroenterol Mex 2006; 71: 351-401.
23. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803-7.
24. Benson A, Barrett T, Sparberg M, et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14: 7-12.
25. Chow DK, Leong RW,. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2007; 6: 479-85.
26. Gonzalez-Lama Y, Gisbert JP, Mate J,. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci 2006; 51: 1833-40.
27. Ullman TA,. Tacrolimus for active ulcerative colitis? Yes! (Even though Cochrane says "no"). Gastroenterology 2007; 132: 1192-4.
28. Hogenauer C, Wenzl HH, Hinterleitner TA, et al. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-23.
29. Olmedo Martin R, Amo Trillo VM, Jimenez Pirez M, et al. Oral tacrolimus in the treatment of refractory severe ulcerative colitis. Gut 2009; 58: A170.
30. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-62.
31. Herrlinger KR, Fellermann K, Stange EF,. Tacrolimus-finally!. Gut 2006; 55: 1224-5.
32. Ng SC, Arebi N, Kamm MA,. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 129-34.
33. Baumgart DC, Wiedenmann B, Dignass AU,. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 1273-81.
34. Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-56.
35. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 589-97.
36. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009; 15: 193-8.
37. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125: 380-8.
38. Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15: 371-7.
39. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-24.
40. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998; 93: 1860-6.
41. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993; 46: 746-94.
42. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-8.
43. Rahier JF, Ben-horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infection in inflammatory bowel disease. J Crohn's & Colitis 2009; 3: 47-91.
44. Ginsburg PM, Dassopoulos T, Ehrenpreis ED,. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Ann Med 2001; 33: 516-25.
45. Bauditz J, Wedel S, Lochs H,. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002; 50: 196-200.
46. Keifer JA, Guttridge DC, Ashburner BP, et al. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001; 276: 22382-7.
47. Vasiliauskas EA, Kam LY, breu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278-87.
48. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-7.
49. Plamondon S, Ng SC, Kamm MA,. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 2007; 25: 557-67.
50. Sabate JM, Villarejo J, Lemann M, et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1117-24.
51. Kitchin JE, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997; 37: 445-9.
52. Ford AC, Towler RJ, Moayyedi P, et al. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 1365-9.
53. Florin TH, Roberts RK, Watson MR, et al. Treatment of steroid refractory inflammatory bowel disease (IBD) with mycophenolate mofetil (MMF). Aust N Z J Med 1998; 28: 344-5.
54. Radford-Smith GL, Taylor P, Florin TH,. Mycophenolate mofetil in IBD patients. Lancet 1999; 354: 1386-7.
55. Palaniappan S, Ford AC, Greer D, et al. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1488-92.
56. Skelly MM, Logan RF, Jenkins D, et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002; 8: 93-7.
57. Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003; 11: 295-302.
58. Forbes A, Britton TC, House IM, et al. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989; 3: 553-6.
59. Ranzi T, Campanini MC, Velio P, et al. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet 1989; 2: 97.
60. Brynskov J, Freund L, Thomsen OO, et al. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet 1989; 1: 721-2.
61. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-7.
62. Gionchetti P, Rizzello F, Morselli C, et al. Review article: problematic proctitis and distal colitis. Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 93-6.
63. Sandborn WJ, Tremaine WJ, Schroeder KW, et al. Cyclosporine enemas for treatment-resistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-5.
64. Qasim A, McDonald S, Sebastian S, et al. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease 1. Scand J Gastroenterol 2007; 42: 194-9.
65. Bonaz B, Boitard J, Marteau P, et al. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2003; 18: 401-8.
66. de BN, Reinisch W, Teml A, et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 2006; 73: 25-31.
67. Ferlitsch A, Teml A, Reinisch W, et al. 6-Thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol 2007; 102: 2495-503. (Pubitemid 47631796)
68. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303.
69. de BN, Zondervan PE, Gilissen LP, et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients 3. Dig Liver Dis 2008; 40: 108-13.
70. de Boer NK, van Bodegraven AA, Jharap B, et al. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 686-94.
71. Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 2002; 47: 1334-41.
72. Abreu MT, Plevy S, Sands BE, et al. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41: 874-88. (Pubitemid 350307073)
73. Pineda AA,. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 (Suppl. 1): S10-4.
74. Sigurbjornsson FT, Bjarnason I,. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 509-16.
75. Domenech E, Hinojosa J, Esteve-Comas M, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004; 20: 1347-52.
76. Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004; 10: 251-7.
77. Kanke K, Nakano M, Hiraishi H, et al. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004; 36: 811-7.
78. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004; 70: 36-44.
79. Ljung T, Thomsen OO, Vatn M, et al. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007; 42: 221-7.
80. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 400-9.
81. Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009; 104: 2990-5.
82. Fernandez-Banares F, Cabre E, Esteve-Comas M, et al. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. J Parenter Enteral Nutr 1995; 19: 356-64.
83. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995; 108: 1056-67.
84. Messori A, Trallori G, d'Albasio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. Scand J Gastroenterol 1996; 31: 267-72.
85. Zachos M, Tondeur M, Griffiths AM,. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001; 3: CD000542.
86. Zachos M, Tondeur M, Griffiths AM,. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007; 1: CD000542.
87. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15: 17-24.
88. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-5.
89. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 1999; 94: 674-8.
90. Borgaonkar M, MacIntosh D, Fardy J, et al. Anti-tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; 2: CD000299.
91. Borgaonkar MR, MacIntosh DG, Fardy JM,. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95: 725-9.
92. Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-9.
93. Marteau P, Sokol H, Dray X, et al. Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? Gastroenterol Clin Biol 2009; 33 (Suppl. 3): S228-34.
94. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-9.
95. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-27.
96. Sang LX, Chang B, Zhang WL, et al. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol 2010; 16: 1908-15.
97. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
98. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
99. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123: 132-42.
100. Rayner CK, Hart AL, Hayward CM, et al. Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 65-71.
101. Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-6.
102. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14.
103. Leung Y, Sparrow MP, Schwartz M, et al. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohn's & Colitis 2009; 3: 162-7.
104. Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 734-41.
105. Ansari A, Patel N, Sanderson J, et al. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-7.
106. Cooper SC, Ford LT, Berg JD, et al. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics 2008; 9: 303-9.
107. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial 4. Gastroenterology 2005; 128: 825-32.
108. Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut 2005; 54: 87-90.
109. Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005; 128: 552-63.
110. Cassinotti A, Annaloro C, Ardizzone S, et al. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 2008; 57: 211-7.
111. Fiorino G, Fries W, De La Rue SA, et al. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem 2010; 17: 1851-7.